The UK Competition Authority opens an investigation into alleged abuse of dominance in the supply of drugs used to treat bipolar disorder (Essential Pharma)

Competition Authority, UK

Previous article The UK Competition Authority investigates a pharmaceutical company for abuse of dominance (Essential Pharma) Next article The Russian Competition Authority investigates whether a pharmaceutical company with a dominant position in the wholesale of certain generics unreasonably refused to conclude a contract for medicine supply (Ipsen / Biotek)

6 Oct 2020

The UK Competition Authority opens an investigation into alleged abuse of dominance in the supply of drugs used to treat bipolar disorder (Essential Pharma)

KEYWORDS

Reference

UK Competition Authority, Essential Pharma, Press release, 6 October 2020

CMA to investigate the supply of bipolar drug* The CMA has opened an investigation into suspected anti-competitive practices in the supply of drugs used to treat bipolar disorder. The Competition and Markets Authority (CMA) will investigate whether the pharmaceutical company Essential Pharma has abused a dominant position in relation to lithium-based

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

UK Competition Authority
United Kingdom’s Competition Authority - CMA (London)

United Kingdom 306 contributions 80014 visits

Quotation

UK Competition Authority, The UK Competition Authority opens an investigation into alleged abuse of dominance in the supply of drugs used to treat bipolar disorder (Essential Pharma), 6 October 2020, e-Competitions October 2020, Art. N° 97274

Visites 190